Shares of AzurRx BioPharma Inc (NASDAQ:AZRX) have received an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus target price of $8.50 for the company and are anticipating that the company will post ($0.24) earnings per share for the current quarter, according to Zacks. Zacks has also assigned AzurRx BioPharma an industry rank of 102 out of 255 based on the ratings given to its competitors.
Several equities research analysts recently commented on AZRX shares. HC Wainwright set a $8.00 price target on AzurRx BioPharma and gave the company a “buy” rating in a report on Tuesday, April 24th. ValuEngine raised AzurRx BioPharma from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.
AzurRx BioPharma (NASDAQ:AZRX) last posted its quarterly earnings results on Monday, May 14th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.11). equities research analysts anticipate that AzurRx BioPharma will post -0.86 earnings per share for the current year.
A hedge fund recently bought a new stake in AzurRx BioPharma stock. Gilder Gagnon Howe & Co. LLC acquired a new position in AzurRx BioPharma Inc (NASDAQ:AZRX) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 555,196 shares of the company’s stock, valued at approximately $1,782,000. Gilder Gagnon Howe & Co. LLC owned 3.31% of AzurRx BioPharma as of its most recent filing with the Securities & Exchange Commission. 8.62% of the stock is currently owned by institutional investors and hedge funds.
About AzurRx BioPharma
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Recommended Story: Earnings Per Share
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.